InPHARM was founded in 1993. First, throughout the 1990s, it represented Boiron in France, then Omega-Pharm in Belgium, Arkopharma in France and then Pleuran in Slovakia. InPHARM has launched products for all these manufacturers, which have been and are still very successful. Examples include Oscillococcinum (influenza), Paranit (infestation) and Immunoglucan (immunity). In their time, these preparations brought new active substances to the Czech and Slovak markets, a new mechanism of action and, in the case of "low dose medicine", also a new therapeutic concept. InPHARM, which has always fulfilled its vision of bringing innovation. To this end, an extensive ten-year revitalization plan was launched in 2007, enriching the portfolio with interesting products such as injectable collagen (Guna-MD injection), effective for osteoarthritis and other musculoskeletal disorders, or infusion therapy with high-dose vitamin C supplemented with its oral form. with liposomal absorption, (Lipo C Askor Forte and Lipo C Askor Junior). The Lipo C Askor range represents the pinnacle of innovation, bringing to market not only a unique patented form of vitamin C with liposomal absorption, but also Uro C Kontrol test strips, which provide information on the body's saturation with vitamin C. This moment can be considered a huge benefit to medicine. and pharmacy, as each person is able to set adequate levels of vitamin C in the body and thus ensure the necessary antioxidant protective capacity of healthy cells and the proper functioning of the immune, nervous, locomotor and cardiovascular systems, ie systems whose proper daily activity is based on vitamin C life dependent. Otherwise, we would further rely on the general recommendation of the daily dose, which is nonsense in the case of vitamin C.
Where does inPHARM operate?
InPHARM currently operates in the Czech Republic and Slovakia and has representative offices in Prague and Bratislava. As indicated above, InPHARM's core business is the development and distribution of pharmaceuticals, medical devices and dietary supplements. The company's strategy is based mainly on the presentation of innovative original products, which it launches on the pharmaceutical market. InPHARM's largest foreign partners are, for example, Guna (Italy), Labolife (France) and dozens of other companies from Italy, Germany, the USA and Australia. InPHARM is not only focused on imports, but also exports its products, currently to Germany, Italy, Vietnam and the USA.
InPHARM's strategy is based on molecular biology
The priority for placing medicines on the market is always the efficacy and safety of the products so that the professional can rely on their declared quality and that their side effects are as close to zero as possible. From this point of view, it can be considered an exceptional project of physiological regulatory medicine, which is based on the restoration of the physiological state of the organism. This is done with the help of the same biologically active molecules that are present in the human body and is done in a very low nano- and picogram concentration, which is close to or identical to the physiological concentration. This medicine works with the latest findings in molecular biology at the level of regulation of communication molecules that represent the nervous system (neuropepetides), endocrine (hormones) and immune (cytokines). It is known that regulatory molecules are crucial for the health of an individual. Today, the disease is perceived as an expression of changes in their concentrations, for example at the level of pro-inflammatory and anti-inflammatory cytokines. And it is physiological regulatory medicine that allows the administration of the already mentioned low de facto physiological concentrations of hormones, neuropeptides, cytokines and growth factors to achieve comparable therapeutic results as when administering these substances at a higher pharmacological concentration, but without side effects. The portfolio of drugs representing physiological regulatory medicine includes over a hundred drugs that are available to prescribers.
InPHARM as a leader in microimmunotherapy
InPHARM's special project is microimmunotherapy, which is represented by Labolife drugs, which contain cytokines and nucleic acids in very low concentrations. Due to their role described above in intercellular signaling, cytokines form the basis of immunomodulation, which they supplement in microimmunotherapeutic preparations with patent-protected nucleic acids. Their mechanism of action is based on influencing the pathological processes involved in the development of the disease, especially such an influence on immunity that blocks the spread of pathogenic microorganisms (viruses, bacteria) or pathologically altered cells (tumors), because nucleic acids prevent the synthesis of proteins needed for these pathological processes. For example, 2LPAPI prevents the spread of papillomavirus infection and thus also prevents the induction of cervical cancer. Similarly, 2LEBV prevents the spread of Epstein-Barr virus, which causes infectious mononucleosis, and recent studies have shown that this virus, in its highly active form, also induces pro-tumor processes, and therefore 2LEBV can also work against carcinogenesis. Microimmunotherapy, this gentle biological treatment, contains more than 30 medicinal products, which are pointed out in the relevant chapter.
InPHARM products support self-healing mechanisms
To offer physicians and the public effective and above all safe innovative products whose mechanism of action is based on the most natural support possible for the adaptation and regulation of physiological functions and whose side effects are at the placebo level. In this respect, the InPHARM concept is fulfilled not only by the already mentioned physiological regulatory medicine and microimmunotherapy, but also, for example, by collagen MD injections, Colenter LD (colostrum with liposomal absorption) and Lipo C Askor (vitamin C with liposomal absorption). Of course, the patient can only benefit from such an effect, as InPHARM's products are physiological and nutritional substances that cannot harm the sick organism, but can only benefit him. As the medical bard and psychiatrist Radkin Honzák aptly states in his recent publication, school medicine is almost never interested in where self-healing physiological mechanisms take place in our organism - and they undoubtedly take place. And it is in the direction of their support, not in the opposite direction, that modern pharmacotherapy should be oriented. And this is the vision and reality of InPHARM, get acquainted with it in detail in the individual chapters.
InPHARM is part of the big three
InPHARM maintains a partnership with Edukafarm and also with the InPHARM Clinic. While Edukafarm develops new innovative products, educates doctors and pharmacists, publishes Bioterapeutics and farmiNEWS, InPHARM Clinic is a carrier of preventive and therapeutic protocols, which are created in cooperation with university clinics from Germany, Italy and the USA. InPHARM itself is a classic pharmaceutical company that has a SÚKL license to distribute drugs to all EU countries, has its own "medical, marketing and sales department" and also its own "sales force", which is represented in the Czech Republic and Slovakia by a team of regional sales representatives. .
- develop and distribute quality, effective and safe products
- ensure their good availability for doctors, pharmacists and the public
- to integrate medical, pharmaceutical and marketing professionals and to promote the use of effective and safe medicine through them
- to support a quality system of postgraduate education of doctors and pharmacists
- to promote awareness of the general public in the field of health and medicines
Today, InPHARM is a fully professional, innovative pharmaceutical company based on a clearly declared concept based on original, safe and innovative products. Their mechanism of action supports the adaptation and regulation of physiological functions, or the achievement of a physiological state of health in a sick organism. The preparations contain the body's own substances (collagen, cytokines, growth factors, hormones, vitamin C, glutathione, colostrum, citicoline, nucleic acids, etc.), the use of which supports the regulation of self-healing mechanisms, which also leads to a reduction in polypragmatism. In fact, it can be said that InPHARM, with the help of Edukafarm and InPHARM Clinic, created a comprehensive concept of application of biogenic substances in order to increase the body's resistance to risk factors causing disruption of health and homeostasis, which is essential in disease prevention and therapy. InPHARM therefore represents a strategy based on an in-depth study of medical physiology, molecular biology, immunology and the issue of effective and rational pharmacotherapy. This approach is exceptional today. Today's pharmacotherapy is often based on the elimination of the symptoms of the disease and not its cause, that such treatment is almost always burdened with side effects, as with few exceptions it counteracts physiological regulation and self-healing mechanisms, where it is not always clear whether such pharmacotherapy predominates. risk when, for example, it impairs immune surveillance. Such pharmacotherapy is expensive and de facto economically destroys the health systems of Western medicine. However, such pharmacotherapy is covered by public health insurance funds, the health care system is economically dependent on it, and therefore still survives. Certainly this strict critique does not apply ad absurdum, yet any initiative that brings gentle and innovative treatment is highly desirable. And that's the way InPHARM goes.
The priority for placing medicines on the market is always the efficacy and safety of the products in question so that the professional can rely on their declared quality and that their side effects are as close to zero as possible. From this point of view, it can be considered an exceptional project of physiological regulatory medicine, which is based on the restoration of the physiological state of a diseased organism. This is done with the help of the same biologically active molecules that are present in the human body and is done in a very low nano and picogram concentration, which is close to or identical to the physiological concentration in which these substances are found in the body. Thus, this medicine works with the latest knowledge of molecular biology at the level of regulation of communication molecules, which represent the nervous system (neuropepetides), endocrine (hormones) and immune (cytokines). It is known that regulatory molecules are crucial for the health of an individual. Today, the disease is perceived as an expression of changes in their concentrations, for example at the level of pro-inflammatory and anti-inflammatory cytokines. And it is physiological regulatory medicine that allows the administration of the already mentioned low de facto physiological concentrations of hormones, neuropeptides, cytokines and growth factors to achieve comparable therapeutic results as when administering these substances at a higher pharmacological concentration, but without side effects. The portfolio of drugs representing physiological regulatory medicine includes over a hundred drugs that are available to prescribers.
In the first decade of the millennium PharmDr. Zdeněk Procházka founded the Edukafarm educational agency in 1998, the aim of which was to support the segment of OTC products, especially in pharmacies, and thus to give pharmacy experts and doctors all the information for their recommendations. At this time, Edukafarm compiled and published over 60 thousand copies of the legendary professional textbook on OTC products and organized thousands of seminars in the Czech Republic and Slovakia in the field of credit chamber education. At this time, InPharm is introducing the Imunoglukan food supplement to the Czech market.
It was the first beta-glucan representing a mixture of polysaccharides, which was an absolute novelty in the Czech Republic. Today, Imunoglukan is the leader in a group of immune stimulating products, and according to IMS data, for example, in 2017, there were approximately 120 products with beta-glucans on the Czech market. However, After a ten-year engagement with Imunoglukan, InPharm is no longer involved, as the manufacturer built its own branch in Prague in 2016. Immunoglucan sales at that time peaked at 0.25 million packages sold annually.
The company inPHARM, in the 1990s acting under the name Rhodon, represented by PharmDr. Zdeněk Procházka, in 1990 he concluded an agreement with the Ministry of Health and the State Institute for Drug Control that homeopathy would be registered in the then Czechoslovakia as medicinal products mostly subject to a medical prescription. PharmDr. Zdeněk Procházka, then the chairman of the Homeopathic Society of the Czech Medical Association JEP, which had over 5,000 active members from the ranks of doctors and pharmacists, was a member of the European Board in Geneva, which participated in compiling documents for EU Council Directive 92/73 / EEC. This Directive was adopted in Brussels on 18 September 1992 and extended the scope of Directives 65/65 / EEC and 75/319 / EEC in the field of medicinal products to include homeopathic medicinal products. In 1997, the first law on medicine in the Czech Republic and Slovakia took over homeopathic legislation, which is enshrined in legislation in Europe, as a European legislation. Rhodon has registered more than 300 types of monocomponent homeopathic remedies in the Czech Republic and Slovakia, including the homeopathic drug Oscillococcinum, the sales of which have led to a turnover of 0.5 million packages per year. After that, the French Boiron opens his own branch in Prague.